PROCEPT BioRobotics Corp

PROCEPT BioRobotics Corp develops and commercializes robotic systems for urology procedures, centered on Aquablation therapy for benign prostatic hyperplasia (BPH). The company sells its systems, single-use handpieces, accessories, and related service offerings primarily in the United States, with additional commercial activity in international markets through direct sales and distributors.

−31,6 %

63,7 %

−31,0 %

+37,2 %

6.85

5.77

— PROCEPT BioRobotics Corp
%
Robotic systems45% Capital equipment used to deliver Aquablation therapy in urology procedures.
Single-use handpieces35% Disposable handpieces used during each Aquablation procedure.
Accessories and probes8% Ancillary components shipped with or used alongside the robotic systems.
Service and repair7% Maintenance, repair, and support services for installed systems.
Leasing and other revenue5% Sales-type leasing arrangements and other related commercial revenue.

The company sells primarily to hospitals in the United States, where the end users are urologists and surgical teams...

  • Hospitalsprimary

    Primary buyers of robotic systems and disposables for hospital-based BPH procedures.

  • Urologists and surgeonsprimary

    Clinical decision-makers who evaluate outcomes, usability, and evidence before adoption.

  • Ambulatory surgery centerssecondary

    Purchase or access systems for outpatient BPH treatment in selected settings.

  • Distribution partnerssecondary

    Support sales, training, and market development outside the United States.

  • Leasing customerssecondary

    Access the systems through sales-type leasing rather than outright purchase.

The United States is the company’s core market and accounted for 88% of revenue in 2025, with 12% from outside the...

  • •United States generated 88% of 2025 revenue
  • •Outside the United States generated 12% of 2025 revenue
  • •Manufacturing is based in San Jose, California
  • •Third-party logistics support shipments from the U.S., U.K., and Netherlands
  • •International growth depends on reimbursement and distributor coverage

The company’s strategy is to expand the installed base of robotic systems, increase procedure utilization, and grow...

01
Expand the installed base of robotic systemsshort-term

More installed systems create future recurring handpiece and service revenue.

02
Improve manufacturing scale and efficiencymedium-term

Higher production volumes can reduce per-unit costs and support margins.

03
Advance next-generation product and software developmentmedium-term

Product improvements help sustain differentiation versus surgical and non-surgical alternatives.

04
Expand reimbursement and market accessshort-term

Coverage and payment determine whether hospitals and physicians adopt the therapy.

The business depends on clinical adoption, reimbursement coverage, and continued regulatory compliance for a medical...

high

Reimbursement and coverage risk

Hospitals and physicians may not adopt Aquablation if payers do not cover the procedure adequately.

Scope
U.S. and international markets
Materiality
high
high

Product safety and recall risk

Adverse events, malfunctions, or manufacturing defects can trigger recalls, reporting obligations, or market restrictions.

Scope
Robotic systems and handpieces
Materiality
high
high

Supplier concentration risk

Many components are sourced from single-source suppliers, so disruptions can affect production and delivery.

Scope
Manufacturing supply chain
Materiality
high
high

Regulatory compliance risk

Failure to meet FDA and other device regulations can lead to delays, sanctions, or loss of approvals.

Scope
U.S. and international regulatory regimes
Materiality
high
medium

Competitive pressure

The company competes against established surgical and non-surgical BPH treatments with broader brand recognition and reimbursement coverage.

Scope
BPH treatment market
Materiality
high
Revenue recognition across multiple product and service streams
Systems, handpieces, leases, and service contracts
Sales-type lease accounting
Capital equipment sales channel
Warranty and post-market obligations
Robotic systems and handpieces
Geographic mix and quarterly seasonality
Revenue and gross margin
Inventory and supply-chain estimates
Cost of sales and inventory valuation

Propanc Biopharma, Inc.

PPCB · Pharmaceutical Preparations

PROTHENA CORP PUBLIC LTD CO

PRTA · Pharmaceutical Preparations

Rezolute, Inc.

RZLT · Pharmaceutical Preparations

PROVECTUS BIOPHARMACEUTICALS, INC.

PVCT · Pharmaceutical Preparations

BIOTRICITY INC.

BTCY · Surgical & Medical Instruments & Apparatus

IO Biotech, Inc.

IOBTQ · Pharmaceutical Preparations

: 29.4.2026